NCCN Guidelines for HR+ HER2 Metastatic Breast Cancer
3 Visningar
• 07/03/23
0
0
Bädda in
administrator
Prenumeranter
Debu Tripathy, MD, and Hatem Soliman, MD, reflect on the NCCN guideline criteria and patient factors that play into decision making for frontline therapy in hormone receptor–positive metastatic breast cancer.
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna